OBJECTIVE： To observe clinical efficacy and safety of linezolid sequential therapy for pediatric gram-positive coccus acute hematogenous osteomyelitis. METHODS： In retrospective study， 13 children with gram-positive coccus acute hematogenous osteomyelitis was collected as research subjects. They received surgery+antibiotics step-down therapy， i.g. linezolid sequential therapy 10 mg/kg orally， q8 h， after symptom relief， body temperature return to normal for 2 weeks and normal lab indexes for 3 times. Clinical efficacy， ADR and lab indexes were observed before and after treatment. RESULTS： Of 13 children， recovery rate of 11 receiving linezolid was 84.62％， no relapse was found in follow-up period； ESR， C-reaction protein， WBC and NEU％ of all children returned to normal except one child suffered from low count of white cell. 3 children suffered from ADR with the incidence of ADR was 23.08％. CONCLUSIONS： Oral administration of linezolid is effective and safe for pediatric gram-positive coccus acute hematogenous osteomyelitis， improve lab index of children and can be utilized as sequential therapy plan in clinic.